| Next-generation, highly-selective S1PR modulator; exhibits highly affinity binding at S1PR1 and S1PR5 |
| Reduces the risk of disability progression on EDSS; improves other clinical and MRI-defined outcomes of disability progression and disease activity (vs placebo) |
| Beneficial effects of treatment sustained |
| Generally well tolerated, with a safety profile similar to that of other S1PR modulators |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.